Table 5.
Univariate and multivariate factors associated with poorer overall survival.
| Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | ||
| Age Cohort | 65–69 years | - | - | - | - | - | - |
| 70–74 years | 1.40 | (0.96–2.05) | 0.081 | 1.22 | (0.77–1.95) | 0.386 | |
| 75–79 years | 1.07 | (0.68–1.68) | 0.772 | 0.85 | (0.46–1.54) | 0.582 | |
| >80 years | 2.20 | (1.47–3.27) | 0.000 | 0.81 | (0.40–1.61) | 0.541 | |
| FIGO stage | 1 | - | - | - | |||
| 2 | 1.30 | (0.55–3.07) | 0.553 | 2.39 | (0.86–6.64) | 0.094 | |
| 3 | 3.69 | (1.98–6.89) | 0.000 | 4.38 | (2.02–9.52) | 0.000 | |
| 4 | 6.00 | (3.08–11.68) | 0.000 | 6.96 | (2.81–17.24) | 0.000 | |
| Surgical outcome | Residual disease | 2.71 | (1.82–4.03) | 0.000 | 2.09 | (1.32–3.30) | 0.002 |
| Platinum- combination | - | - | - | - | - | - | |
| Chemotherapy | Single-agent carboplatin | 1.29 | (0.93–1.77) | 0.123 | 1.34 | (0.85–2.17) | 0.203 |
| No chemotherapy | 2.19 | (1.43–3.35) | 0.000 | 4.49 | (1.99–10.13) | 0.000 | |
| Completed 6 cycles | 0.34 | (0.23–0.49) | 0.000 | 0.33 | (0.19–0.59) | 0.000 | |